Uricosuric effect of irtemazole in hyperuricemic patients without and with renal insufficiency.
A single oral dose of 50 mg irtemazole exhibited a clear cut uricosuric effect in five patients with hyperuricemia and normal renal function. The average maximal decrease of plasma uric acid was 46.1% compared to the initial value; it was reached between 6 h and 12 h after drug administration. Extent and course of plasma uric acid showed no differences between normouricemic (5) and hyperuricemic subjects. In four patients suffering from hyperuricemia and renal insufficiency only a minor effect of irtemazole was seen. The average maximal decrease of plasma uric acid reached 12.8% compared to the initial value. It occurred between 8 h and 12 h after drug ingestion. In both normouricemic and hyperuricemic subjects irtemazole acts more quickly than benzbromarone and probenecid. The duration of its uricosuric effect is shorter. Like benzbromarone, irtemazole exhibits only a minor effect in patients with reduced creatinine clearance.
Kamilli
I
I
Medizinische Poliklinik, Universität München.
Gresser
U
U
Pellkofer
T
T
Löffler
W
W
Zöllner
N
N
D000328:Adult; D000368:Aged; D001562:Benzimidazoles / Q000627:therapeutic use*; D005260:Female; D006073:Gout / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D014527:Uric Acid / Q000097:blood*; D014528:Uricosuric Agents / Q000627:therapeutic use*
D001562:Benzimidazoles; D014528:Uricosuric Agents; D014527:Uric Acid; C060889:irtemazole